Effect of ECM Ligands on RPE Reattachment to Bruch's: II
About the Research Project
Program
Award Type
Standard
Award Amount
$37,500
Active Dates
April 01, 2000 - March 31, 2001
Grant ID
M2000018
Summary
The transplantation of retinal pigmented epithelial (RPE) cells following surgery to eliminate CNV has had only limited success so far because the transplanted cells fail to survive. In previous research, which includes last year’s MDR-funded study, Dr. Del Priore found that, in order to survive, the transplanted RPE cells must attach to an important supporting structure known as Bruch’s Membrane (BM). A number of complications can affect the attachment process, and some of these variables are being examined systematically in vitro to identify conditions that optimize the attachment and survival of transplanted RPE. If successful, the in vitro optimization can then be used to maximize the chance of successful RPE transplantation in animals and humans.
Grantee institution at the time of this grant: University of Medicine and Dentistry of New Jersey
Related Grants
Macular Degeneration Research
Development of an Oral Treatment for Dry AMD Using Everyday Anti-Inflammatory Drugs
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Marco Bassetto, PhD
Current Organization
University of California, Irvine
Development of an Oral Treatment for Dry AMD Using Everyday Anti-Inflammatory Drugs
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Marco Bassetto, PhD
Current Organization
University of California, Irvine
Macular Degeneration Research
Developing a New Treatment for Wet AMD: Targeted Removal of a Disease-Causing Protein
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Celia Bisbach, PhD
Current Organization
University of Wisconsin-Madison
Developing a New Treatment for Wet AMD: Targeted Removal of a Disease-Causing Protein
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Celia Bisbach, PhD
Current Organization
University of Wisconsin-Madison
Macular Degeneration Research
Sterically Hindered Phenol, PMC, as a Potential Novel Therapeutic for Geographic Atrophy
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Suman Chaudhary, PhD
Current Organization
Schepens Eye Research Institute of Mass. Eye and Ear
Sterically Hindered Phenol, PMC, as a Potential Novel Therapeutic for Geographic Atrophy
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Suman Chaudhary, PhD
Current Organization
Schepens Eye Research Institute of Mass. Eye and Ear